Cannabinoid Control of Fear Extinction Neural Circuits in Humans

Healthy Participants Clinical Trial

Official title:

Cannabinoid Control of Fear Extinction Neural Circuits in Humans

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02472847
• Other study ID #: 2012-0242
• Secondary ID: R21MH093917
• Status: Completed
• Phase: Phase 4
• First received: June 12, 2015
• Last updated: July 28, 2015
• Start date: May 2012
• Est. completion date: July 2014

Study information

• Verified date: July 2015
• Source: University of Illinois at Chicago
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The goal of the current proposal is to investigate the effects of a cannabinoid drug on the memory of extinguished fear in humans and the brain circuitry important for the recall of extinction learning. The investigators findings will translate previous discoveries from animal studies to humans and increase their understanding of the neurobiological mechanisms supporting retention of extinction memory. This proof-of-concept study is a critical translational first step towards the development of cannabinoid modulators as an adjunctive strategy to exposure-based therapies to augment extinction learning and prevent the return of fear memories in patients with post-traumatic stress and other anxiety disorders.

Description:

The inability to suppress inappropriate fear responses is the hallmark of anxiety disorders, such as posttraumatic stress disorder (PTSD), panic, and phobia disorders. Extinction of fear occurs during exposure therapy; however, this is temporary and fear often re-emerges with the passage of time (spontaneous recovery), undermining the maintenance of therapeutic gains. Enhancing the neural and neurochemical substrates involved in retention of extinction memory will be critical to solving this challenge. Animal studies have shown that activation of the cannabinoid system within the amgydala, hippocampus, and ventromedial prefrontal cortex (AMYG, HPC, vmPFC, respectively), brain structures critical to fear expression and extinction learning, enhances fear extinction and its retention. Specifically, CB1 receptor agonists, such as Δ9-tetrahydrocannibinol (THC), can facilitate extinction recall by preventing recovery of extinguished fear in rats. However, this phenomenon has not been, but should be, investigated in humans. This proof-of-concept project specifically aims to assess the effects of THC on the recall of extinction learning and underlying neural circuit activation (HPC, vmPFC) when tested 24 hours and 1 week after extinction training, and to determine if the maintenance of extinction retention (1 week later) is mediated by the enhancement of vmPFC-HPC activation by THC observed during a recall test 24 hours after extinction learning. In a randomized, double-blind, placebo-controlled, between-subjects design, the investigators will couple a standard Pavlovian fear extinction paradigm in fMRI and simultaneous skin conductance recordings with an acute pharmacological challenge with oral, synthetic THC prior to extinction learning in healthy adult volunteers (n=80) and test extinction retention and maintenance of extinction learning at 24 hours and 1 week later, as well as fear renewal. This proof-of-concept study provides the most translational, impactful, informative, and critical test and first step towards the development of cannabinoid modulators as an adjunctive strategy to exposure-based therapies to augment extinction retention and prevent the return of fear memories in patients with PTSD and other anxiety disorders.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 85
• Est. completion date: July 2014
• Est. primary completion date: July 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 21 Years to 45 Years

Eligibility

Inclusion Criteria:

1. age 21-45

2. right-handed

3. free of lifetime diagnosis of Axis I psychiatric disorder

4. must be able to given informed consent

5. must be medically and neurologically healthy.

Exclusion Criteria:

1. any current medical condition requiring psychoactive/psychotropic medication or medication that would interact with dronabinol or interfere with study procedures

2. current or past allergic or adverse reaction or known sensitivity to cannabinoid-like substance (Dronabinol /Marijuana/Cannabis/THC, cannabinoid oil, sesame oil, gelatin, glycerin, and titanium dioxide.)

3. any current or past Axis I psychiatric disorder, including alcohol/substance abuse or dependence disorder

4. less than a high school education

5. lack of fluency in English

6. night shift work

7. currently pregnant or planning pregnancy or lactating (women)

8. unwilling/unable to sign informed consent document

9. inability to tolerate small, enclosed spaces without anxiety (e.g. claustrophobia), as determined by self-report and a preliminary session in a mock scanner

10. left-handed

11. presence of ferrous-containing metals within the body (e.g., aneurysm clips,shrapnel/retained particles)

12. under 21 or over 45 years of age

13. anticipation of a required drug test in the 4 weeks following the study. No vulnerable participant populations will be included in this study

14. participation in an experiment involving shocks in the last 6 months.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Healthy Participants

Intervention

Drug:
• Dronabinol
Dronabinol (7.5mg) is administered only once by the oral route and is placed in opaque capsules with dextrose filler. Half of the participants will receive dronabinol.
• Placebo
Placebo is administered only once by the oral route and contains only dextrose in opaque capsules. Half of the participants will receive placebo.

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
University of Illinois at Chicago	National Institute of Mental Health (NIMH), National Institutes of Health (NIH)

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	BOLD Signal Measured by Functional Magnetic Resonance Imaging (fMRI)	Mean BOLD hippocampal signal during extinction learning and retention task in brain responsebetween the placebo (PBO) and the dronabinol (THC) group. Target areas are analyzed from fMRI scans. The scans were completed on days 1, 2, 3, and 9. Participants were randomized to the PBO and THC condition and received either placebo or dronabinol on day 2, 2 hours prior to extinction learning. Data from days 1, 2, 3, & 9 was combined and a single value was averaged for each group.	Day 1, 2, 3, & 9	No